Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock

Stemline Therapeutics (Nasdaq:STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, announced the pricing of an underwritten public offering of 8,888,889 shares of its common stock at a price of $9.00 per share, with expected gross proceeds to Stemline of $80 million.

As quoted in the press release:

Due to demand, this offering was upsized from the previously announced 6,600,000 shares. Stemline has also granted the underwriters a 30-day option to purchase up to 1,333,333 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on January 18, 2019, subject to customary closing conditions.

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co., LLC are acting as co-lead managers and Roth Capital Partners, LLC, ThinkEquity, a division of Fordham Financial Management, Inc., A.G.P./Alliance Global Partners, National Securities Corporation, and Aegis Capital Corp. are acting as co-managers for the offering.

Click here to read the full press release.